Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582840 | 0.84 | TMEM97 (0.53) | TMEM97SIGMAR1HTR3AHTR4MEN1 | |
| SCHEMBL6588314 | 0.84 | TMEM97 (0.50) | TMEM97SIGMAR1HTR3AHTR4APEX1 | |
| SCHEMBL8947427 | 0.83 | KDM4E (0.54) | MEN1KMT2APGRALDH1A1 | |
| SCHEMBL2267441 | 0.81 | KDM4E (0.47) | APEX1MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4621924 | 0.80 | ALDH1A1 (0.59) | APEX1MEN1KMT2AGAAPGR | |
| SCHEMBL7645474 | 0.80 | APEX1 (0.48) | APEX1GAA | |
| SCHEMBL6948825 | 0.80 | MEN1 (0.46) | TMEM97SIGMAR1HTR3AHTR4APEX1 | |
| SCHEMBL5329443 | 0.79 | APEX1 (0.82) | APEX1MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL28357637 | 0.78 | MEN1 (0.51) | TMEM97SIGMAR1HTR3AHTR4MEN1 | |
| SCHEMBL28357639 | 0.77 | KDM4E (0.39) | TMEM97SIGMAR1HTR3AHTR4APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5552408-A | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1996-09-03 | — | — | US | claimed |
| US-5358954-A | Antiserotonine agent, antiemetic, gastrointestinal disorders | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-10-25 | — | — | US | claimed |
| US-5223511-A | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1993-06-29 | — | — | US | claimed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-12-04 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | disclosed |
| WO-2010044585-A2 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-15 | — | — | US | disclosed |
| EP-0815080-B1 | DI-SUBSTITUTED 1,4-PIPERIDINE ESTERS AND AMIDES HAVING 5-HT4 ANTAGONISTIC ACTIVITY | BOEHRINGER INGELHEIM ITALIA (IT) | 2004-06-16 | — | — | EP | disclosed |
| US-6002009-A | Di-substituted 1,4-piperidine esters and amides having 5-HT4 antagonistic activity | BOEHRINGER INGELHEIM ITALIA, S.P.A. (IT) | 1999-12-14 | — | — | US | disclosed |
| EP-0815080-A1 | DI-SUBSTITUTED 1,4-PIPERIDINE ESTERS AND AMIDES HAVING 5-HT 4? ANTAGONISTIC ACTIVITY | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028424-A1 | DI-SUBSTITUTED 1,4-PIPERIDINE ESTERS AND AMIDES HAVING 5-HT4 ANTAGONISTIC ACTIVITY | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1996-09-19 | — | — | WO | disclosed |
| US-5552408-A | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1996-09-03 | — | — | US | disclosed |
| US-5358954-A | Antiserotonine agent, antiemetic, gastrointestinal disorders | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-10-25 | — | — | US | disclosed |
| US-5223511-A | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1993-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | TMEM97 1865/4885SIGMAR1 918/4885HTR3A 893/4885 |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | PGC, VIP, PIGO | TMEM97 1865/4885SIGMAR1 918/4885HTR3A 893/4885 |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | PGC, VIP, PIGO | TMEM97 1865/4885SIGMAR1 918/4885HTR3A 893/4885 |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | TMEM97 1865/4885SIGMAR1 918/4885HTR3A 893/4885 |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | TMEM97 1865/4885SIGMAR1 918/4885HTR3A 893/4885 |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | TMEM97 1865/4885SIGMAR1 918/4885HTR3A 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.